B-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Recent gene profiling studies have identified a new breast cancer subtype, the basal-like group, which expresses genes characteristic of basal epithelial cells and is associated with poor clinical outcomes. However, the genes responsible for the aggressive behavior observed in this group are largely unknown. Here we report that the small heat shock protein alpha-basic-crystallin (alphaB-crystallin) was commonly expressed in basal-like tumors and predicted poor survival in breast cancer patients independently of other prognostic markers. We also demonstrate that overexpression of alphaB-crystallin transformed immortalized human mammary epithelial cells (MECs). In 3D basement membrane culture, alphaB-crystallin overexpression induced luminal filling and other neoplastic-like changes in mammary acini, while silencing alphaB-crystallin by RNA interference inhibited these abnormalities. alphaB-Crystallin overexpression also induced EGF- and anchorage-independent growth, increased cell migration and invasion, and constitutively activated the MAPK kinase/ERK (MEK/ERK) pathway. Moreover, the transformed phenotype conferred by alphaB-crystallin was suppressed by MEK inhibitors. In addition, immortalized human MECs overexpressing alphaB-crystallin formed invasive mammary carcinomas in nude mice that recapitulated aspects of human basal-like breast tumors. Collectively, our results indicate that alphaB-crystallin is a novel oncoprotein expressed in basal-like breast carcinomas that independently predicts shorter survival. Our data also implicate the MEK/ERK pathway as a potential therapeutic target for these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Parkin, D. M., Pisani, P., & Ferlay, J. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.33 · Cited by 3,376
Cited by
Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,285
Basal-Like Breast Cancer: A Critical Review
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1748 · Cited by 1,164
Hennessy, B. T., Gonzalez-Angulo, A.-M., Stemke-Hale, K., Gilcrease, M. Z., Krishnamurthy, S., Lee, J.-S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3441 · Cited by 874
Triple-negative breast cancer: disease entity or title of convenience?
Carey, L., Winer, E., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 783
Badve, S., Dabbs, D. J., Schnitt, S. J., Baehner, F. L., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.200 · Cited by 680
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
Anders, C. K., & Carey, L. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.008 · Cited by 625
Mani, S. A., Yang, J., Brooks, M., Schwaninger, G., Zhou, A., Miura, N., Kutok, J. L., Hartwell, K., Richardson, A. L., & Weinberg, R. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703900104 · Cited by 575
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini, K. S., Viale, G., Loi, S., Bradbury, I., Bliss, J. M., Azim, H. A., Ellis, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2010 · Cited by 465
Hoeflich, K. P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H., Punnoose, E., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 463
How basal are triple‐negative breast cancers?
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23518 · Cited by 443
Catechol Polymers for pH-Responsive, Targeted Drug Delivery to Cancer Cells
Su, J., Chen, F., Cryns, V. L., & Messersmith, P. B. (2011) · Journal of the American Chemical Society · doi:10.1021/ja203077x · Cited by 441
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., Sledge, G. W., & Carey, L. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437
Basal Breast Cancer: A Complex and Deadly Molecular Subtype
Bertucci, F., Finetti, P., & Birnbaum, D. (2012) · Current Molecular Medicine · doi:10.2174/156652412798376134 · Cited by 394
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
Tischkowitz, M., Brunet, J.-S., Bégin, L. R., Huntsman, D. G., Cheang, M. C., Akslen, L. A., Nielsen, T. O., & Foulkes, W. D. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-134 · Cited by 365
Hsp27 (HspB1) and αB‐crystallin (HspB5) as therapeutic targets
Arrigo, A.-P., Simon, S., Gibert, B., Kretz-Remy, C., Nivon, M., Czekalla, A., Guillet, D., Moulin, M., Diaz-Latoud, C., & Vicart, P. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.04.033 · Cited by 305
Acunzo, J., Katsogiannou, M., & Rocchi, P. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.04.002 · Cited by 280
EGFR associated expression profiles vary with breast tumor subtype
Hoadley, K. A., Weigman, V. J., Fan, C., Sawyer, L. R., He, X., Troester, M. A., Sartor, C. I., Rieger-House, T., Bernard, P. S., Carey, L. A., et al. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-258 · Cited by 278
Triple negative breast cancers: Clinical and prognostic implications
Dawson, S. J., Provenzano, E., & Caldas, C. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70013-9 · Cited by 266
Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update
Ciocca, D. R., Arrigo, A. P., & Calderwood, S. K. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0918-z · Cited by 265
Head and neck cancer: past, present and future
Chin, D., Boyle, G. M., Porceddu, S., Theile, D. R., Parsons, P. G., & Coman, W. B. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.1111 · Cited by 255
A Nuclear Phosphoinositide Kinase Complex Regulates P53
Choi, S., Chen, M., Cryns, V. L., & Anderson, R. A. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0297-2 · Cited by 106
Metadata
- Authors
- Moyano, J. V.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-12-08
- Volume
- 116
- Issue
- 1
- Pages
- 261-270
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2145444267
- Cited by
- 272
- References
- 44
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.